Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters

Clonal ZEB1-driven mesenchymal transition promotes targetable oncologic anti-angiogenic therapy resistance

(2020) Ankush Chandra et al.   CANCER RESEARCH

The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads

(2019) Yang Liao et al.   NUCLEIC ACIDS RESEARCH

Astrogliogenesis in human fetal brain: complex spatiotemporal immunoreactivity patterns of GFAP , S100, AQP 4 and YKL ‐40

(2019) Camilla Bjørnbak Holst et al.   JOURNAL OF ANATOMY

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

(2019) Cyril Neftel et al.   CELL

Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma

(2019) Dieter Henrik Heiland et al.   Nature Communications

Experimental models and tools to tackle glioblastoma

(2019) Faye L. Robertson et al.   Disease Models & Mechanisms

Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma

(2019) Julian Wurm et al.   Cancers

Patient-Derived Glioma Models: From Patients to Dish to Animals

(2019) Cintia Carla da Hora et al.   Cells

The current state of immunotherapy for gliomas: an eye toward the future

(2019) Peter E. Fecci et al.   JOURNAL OF NEUROSURGERY

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance

(2018) Signe R Michaelsen et al.   NEURO-ONCOLOGY

Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis

(2018) Do-Hyun Kim et al.   Nature Communications

The complement system in glioblastoma multiforme

(2018) T. A. M. Bouwens van der Vlis et al.   Acta Neuropathologica Communications

Current trends in mouse models of glioblastoma

(2017) Masafumi Miyai et al.   JOURNAL OF NEURO-ONCOLOGY

The Landscape of Isoform Switches in Human Cancers

(2017) Kristoffer Vitting-Seerup et al.   MOLECULAR CANCER RESEARCH

Salmon provides fast and bias-aware quantification of transcript expression

(2017) Rob Patro et al.   NATURE METHODS

New Directions in Anti-Angiogenic Therapy for Glioblastoma

(2017) Nancy Wang et al.   Neurotherapeutics

Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1

(2017) N Cohen et al.   ONCOGENE

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

(2017) Mogens K. Boisen et al.   Oncotarget

Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis

(2016) Gang Qin et al.   MOLECULAR NEUROBIOLOGY

BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity

(2016) Rikke D. Rasmussen et al.   Nature Communications

Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population

(2015) Alisa D. Kjaergaard et al.   INTERNATIONAL JOURNAL OF CANCER

Current status and future directions of anti-angiogenic therapy for gliomas

(2015) Wolfgang Wick et al.   NEURO-ONCOLOGY

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization

(2015) Rong Shao et al.   Oncotarget

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Directed against Human YKL-40 Increases Tumor Volume in a Human Melanoma Xenograft Model in Scid Mice

(2014) Johannes Salamon et al.   PLoS One

Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma

(2013) R. Shao et al.   CARCINOGENESIS

Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition

(2013) Y. Piao et al.   CLINICAL CANCER RESEARCH

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

In vivo models of primary brain tumors: pitfalls and perspectives

(2012) P. C. Huszthy et al.   NEURO-ONCOLOGY

Camera: a competitive gene set test accounting for inter-gene correlation

(2012) Di Wu et al.   NUCLEIC ACIDS RESEARCH

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Plasma YKL-40 levels in healthy subjects from the general population

(2011) Stig E. Bojesen et al.   CLINICA CHIMICA ACTA

Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells

(2011) Chun-Chuan Chen et al.   CLINICAL IMMUNOLOGY

Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme

(2011) Marie-Thérése Stockhausen et al.   EXPERIMENTAL CELL RESEARCH

Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma

(2011) Ralph A. Francescone et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A YKL-40-Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers

(2011) M. Faibish et al.   MOLECULAR CANCER THERAPEUTICS

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

The paradoxical effect of bevacizumab in the therapy of malignant gliomas

(2010) E. M. Thompson et al.   NEUROLOGY

A scaling normalization method for differential expression analysis of RNA-seq data

(2010) Mark D Robinson et al.   GENOME BIOLOGY

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma

(2009) Myung Jin Son et al.   Cell Stem Cell

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

A role for VEGF as a negative regulator of pericyte function and vessel maturation

(2008) Joshua I. Greenberg et al.   NATURE